51 results about "Tumor suppressor proteins" patented technology

The invention relates to isolated polynucleotides homologous with a portion of one strand of the human tumor suppressor gene, FEZ1, and to the tumor suppressor protein encoded thereby, Fez1. The polynucleotides are useful, for example, as probes, primers, portions of expression vectors, and the like. The invention also includes diagnostic, therapeutic, cell proliferation enhancement, and screening methods which involve these polynucleotides and protein. The invention further includes kits useful for performing the methods of the invention.

The invention belongs to the field of medicinal preparation, relates to a co-feeding delivery system, and particularly relates to a co-feeding lipid nano-delivery system for entrapping anticancer polypeptide and gene or chemotherapeutics or radiopharmaceutical simultaneously. The delivery system consists of a target searching material, a lipid component and medicaments, ensures that different medicaments are entrapped to the lipid nano-delivery system together by sufficiently utilizing character difference among components or entrapping through static electricity or a method of passively combining and actively carrying, and can simultaneously deliver the anticancer polypeptide and genetic medicament capable of restoring activity of tumor suppressor protein p53 or chemotherapeutics or radiopharmaceutical into a target cell so as to achieve the aim of co-therapy. By virtue of in-vitro activity evaluation, the system is proved to be superior to that of delivering single component at the same time, the anticancer activity of the system is remarkably improved, and the system has definite co-therapy effect.

Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and / or CpG oligodeoxynucleotide immunomodulators.

Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy. Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL-response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and / or CpG oligodeoxynucleotide immunomodulators.

The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

An isolated sequence or peptide isolated from an E2, E4, E6, E7 early or late coding region of human papillomavirus (HPV) that is soluble in aqueous medium, and characterized by a linkage to another protein sequence or peptide isolated from the E2, E4, E6, E7 early or late coding region of HPV by a spacer sequence, wherein the isolated protein sequence or peptide consists of more than 50% hydrophilic amino acids, and is recognized by a specific antibody of HPV. Also disclosed are isolated protein sequences or peptides from Harvey Ras (H-Ras), Kirsten Ras (K-Ras), and phosphatase and tensin homologue (PTEN) tumor suppressor proteins and Chlamydia trachomatis heat shock protein 60 (CHSP60 groEL1) and methods for detecting or diagnosing cancer or cellular abnormalities.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses a nanometer vesica capable of detecting wild type p53 protein and variant p53 protein in cells simultaneously. Nanogold capable of specifically recognizing wild type p53 protein wraps inside the vesica, and an antibody resisting variant p53 protein marked by fluorescein isothiocyanate decorates the surface of the vesica. The nanometer vesica has the advantages that (1) the nanometer vesica recognizes different types of tumor suppressor proteins p53 with high specificity, and the detection specificity and the sensitivity are improved; (2) plasma resonance imaging and fluorescence imaging technologies are adopted, after the vesica enters the cell, the cell is subjected to in-situ imaging by adopting a microscope, and wild type p53 protein and variant p53 protein on the single-cell layers are detected simultaneously; (3) the nanometer vesica designed according to the technical scheme is capable of carrying out in-situ monitoring on variation of expression of p53 protein in the cell under the action of medicine, and a novel method is provided for researching physiological process in the cell participated by the vesica.

The invention relates to the technical field of medical treatment. The tea double-chlorine carboxamide and tea double-bromine carboxamide are newly synthesized compounds which can inhibit growths and invasions of cancer cells such as lung cancer, breast cancer, liver cancer, stomach cancer, colon cancer, prostate cancer, pancreatic cancer, cervical cancer, lymphoma, leukemia, and melanoma, and can obviously inhibit the tumor growth and metastasis in the body, and the inhibition effect of the compound is better than that of an anticancer medicament; the mechanism of action involves a receptor which is closely related to down-regulation and inhibition of the growth, invasion and metastasis of a tumor, signal transduction and regulation protein and kinase levels and a binding of a nuclear factor and DNA (Deoxyribonucleic Acid), and up-regulation of factors such as tumor suppressor proteins and cell cycle inhibitor proteins simultaneously; double tea chlorine carboxamide and double tea chlorine carboxamide can directly inhibit activities of histone deacetylase and histone methyltransferase EZH2(Enhancer Of Zeste Homolog 2) and the binding of the inflammatory factor NF-kB and DNA, and the activities of tea double-chlorine carboxamide and tea double-bromine carboxamide are better than that of the clinical anti-cancer medicament. The invention provides new applications of tea double-chlorine carboxamide and tea double-bromine carboxamide and intermediate compounds in preventing and treating the diseases such as cancers, inflammation, cardiovascular and immune deficiencies.

The present invention pertains to peptide-containing complexes / nanoparticles that are useful for delivering into a cell one or more mRNA (such as therapeutic mRNA, e.g., mRNA encoding a tumor suppressor protein).

The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell suface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The invention discloses an escherichia coli Nissle 1917 anti-tumor targeted engineering bacterial strain as well as a construction method and application thereof. The escherichia coli Nissle 1917 anti-tumor targeted engineering bacterial strain is collected in China Center For Type Culture Collection on June 26, 2018, with the culture collection number of CCTCC NO: M 2018403; the classification name thereof is escherichia coli EcN (Tum 5-p53), and the Latin scientific name thereof is Escherichia coli Nissle (Tum 5-p53). The constructed escherichia coli EcN (Tum 5-p53) contains an anti-tumor hypoxic expression vector pET28a-Pvhb-SUMO-Tum 5-MMP-p53, can efficiently express bifunctional protein Tum 5-p53, can transmit an antiangiogenic factor Tum-5 and tumor suppressor protein p53 to a solidtumor, and plays a good anti-tumor therapeutic effect. The tumor inhibiting rate of the anti-tumor targeted engineering bacterial strain on a human liver cancer SMMC-7721 nude mouse is as high as 69.47%.

The present invention belongs to the field of pharmaceutical preparations, and relates to a polypeptide drug delivery system, particularly to a micelle preparation entrapped with binding peptide polymer with specific anti-cancer activity. The drug delivery system consists of a targeted functional material, an amphiphilic block copolymer and a binding peptide. By entrapping a binding peptide capable of restoring the activity of a tumor suppressor protein p53, the binding peptide is delivered into cancer cells to exert the activity of inhibiting tumor cell growth and increase targeted anti-cancer effect; and the binding peptide has better anti-cancer effect by combination with temozolomide. By in vivo and in vitro active valuation, the drug delivery system is proved to be able to successfully deliver binding peptides to the target site and send binding peptides into the target cells, and has clear therapeutic effect.

A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.

The invention discloses application of OTUD3 protein in preparing products for inhibiting tumor growth. The OTUD3 protein or an encoding gene of the OTUD3 or a recombinant vector containing the encoding gene of the OTUD3 or lentivirus expressing the OTUD3 protein can be applied to preparation of a product with at least one of the functions from (1) to (7) as shown in the specification. Experiments prove that the OTUD3 serving as a newly discovered important tumor suppressor protein is capable of inhibiting generation and metastasis of tumors, and discovery of the OTUD3 functions provides important scientific basis and application value to tumor diagnosis, prevention and treatment.

The invention discloses 168 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of, and including, EGFR kinase, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor / Scaffold proteins, Calcium-Binding Proteins, Cell Cycle Regulation proteins, Cytoskeletal proteins, DNA Binding and Replication Proteins, GTPase Activating proteins, Guanine Nucleotide Exchange Factor proteins, Lipid Kinases, Receptor Tyrosine Kinases, Receptor Tyrosine Kinase ligands, Protein Kinases, Receptor and Protein Phosphatases, Transcription Factor proteins, Tumor Suppressor proteins, and Vesicle proteins.

The invention discloses a novel application of gastrin in inhibiting gastrointestinal tumor tumors. Gastric cancer target gene anion exchange protein 1 is interacted with tumor suppressor protein p16 so as to induce gastric cancer, however, 17 peptide gastrin (H-pGlu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) can effectively inhibit expression of gastric cancer target gene AE1 and p16 and breaks through the traditional view that gastrin induces tumors, and clinical pathologies show that the gastrin has obvious negative correlation with AE1 and p16. The invention alsodiscloses that the gastrin with the concentration of 10-10mol / L-10-70mol / L has obvious inhibition effect on gastric cancer cell activity after a certain time, thus prompting that the gastrin has curing effect on gastric antrum cancer and providing a new direction for curing gastric cancer based on the test results.

Disclosed is an isolated tumor suppressor protein inducible by tumor necrosis factor. Also disclosed are isolated cDNA molecules encoding the doc-1, a tumor suppressor protein, cells transformed with this cDNA, antibodies specific for and reactive with the doc-1 protein, and methods of using these proteins, cDNAs, and antibodies.

The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites / proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor / scaffold proteins, adhesion / extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding / repair / replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G / regulator proteins, inhibitor proteins, motor / contractile proteins, phosphatase, protease, Ser / Thr protein kinases, Protein kinase (Tyr)s, receptor / channel / cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.

The present invention pertains to peptide-containing complexes / nanoparticles that are useful for delivering into a cell one or more mRNA (such as therapeutic mRNA, e.g., mRNA encoding a tumor suppressor protein).

The invention presents methods of identifying small molecule compounds that are activators of tumor suppressor protein p53 pathway, and its associated family members p63 and p73, function. The invention is further drawn to methods of killing tumor cells and treating cancers or other conditions requiring activation of the p53 family member pathways and DNA damage response pathways with the small molecules.

The invention relates to a method for extracting tumor suppressor protein from the amniotic fluid of pregnant women, which comprises (1) collecting amniotic fluid, (2) filtering amniotic fluid, (3) centrifugally depositing, (4) first depressurizing and drying, (5) first dialysis: using the dialysis bag whose molecular weight cutoff is 10000Dalton, (6) second depressurizing and drying, (7) second dialysis: using the dialysis bag whose molecular weight cutoff is 3000Dalton, (8) third depressurizing and drying. The extraction method has the advantages that the invention can extract tumor suppressor protein from the amniotic fluid, thereby developing a new route of tumor suppressor protein, and test result proves that mice in tumor experiment can be healed, the tumor suppressor protein of the amniotic fluid of pregnant women can act the mice tumor, the protein has specific wide spectrum anti-tumor function and the invention is beneficial to express the biological function of amniotic fluid, providing the function of embryo growth information channel.

The invention has disclosed a new tumor suppressor protein HCRP1, the polynucleotide sequences encoding this polypeptides, and methods for production of the polypeptide using the recombinant technology. The tumor suppression protein, HCRP1, is obtained through the positional candidate cloning strategy. It locates in 8p22 region of human chromosome. The full length cDNA for HCRP1 is 1917bp, which encodes a protein of 397 amino acids. When introduced into liver cancer cells, HCRP1 can inhibit the malignant transformation of liver cancer cells.

A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses.